<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324960</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-Aza-ceplene</org_study_id>
    <nct_id>NCT01324960</nct_id>
  </id_info>
  <brief_title>Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase I and Phase II Study of the Efficacy and Safety of Maintenance Treatment With Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Who Achieved Hematological Response to Azacitidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EpiCept Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I study of azacitidine with Ceplene/interleukin-2 will first evaluate the safety and
      tolerability of this regimen in patients with higher risk myelodysplastic syndromes (MDS) who
      achieved a hematological response after 6 cycles of azacitidine. After approval by an
      independent Data Safety Monitoring Board (DSMB), the phase I study will be followed by an
      open label randomized phase II study designed to characterize the efficacy, safety, and
      tolerability of the addition of Ceplene/interleukin-2 to azacytidine in patients with higher
      risk myelodysplastic syndrome (MDS) who achieved a hematological response after 6 cycles of
      azacitidine.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression according to IWG2006 criteria</measure>
    <time_frame>Every 4 cycles (during average 2 years)</time_frame>
    <description>Progression will be assessed by monitoring the bone marrow, blood and hematologic supportive care according IWG 2006 criteria .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Types and numbers of adverse events occuring in all treated patients</measure>
    <time_frame>Every cycle, during the follow-up on average during 2 years</time_frame>
    <description>The safety profile will be determine by assessements of clinical symptoms, physical examinations, vital signs and clinical laboratory tests. The types and numbers of adverse events occuring in all treated patients will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the quality and the duration of responses compared to maintenance with AZA alone</measure>
    <time_frame>While patient is on study, during follow up on average during 2 years</time_frame>
    <description>The response will be assessed every 4 cycles according IWG 2006 criteria and it will be evaluated if there is an improvement of the level of response and the response duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Ceplene® / IL2 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceplene®, IL-2, Azacitidine</intervention_name>
    <description>Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.</description>
    <arm_group_label>Ceplene® / IL2 + Azacitidine</arm_group_label>
    <other_name>Human recombinant IL-2 = Aldesleukin® (Novartis)</other_name>
    <other_name>Azacitidine = Vidaza® (Celgene)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks</description>
    <arm_group_label>Azacitidine</arm_group_label>
    <other_name>Azacitidine = Vidaza® (Celgene)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Must understand and voluntarily sign an informed consent form

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Documented diagnosis of MDS according to WHO classification, that meets IPSS criteria
             for intermediate-2 or high-risk disease

          -  Must have achieved a response (CR, PR, mCR or HI according to IWG 2006 criteria) after
             6 cycles of Azacitidine.

          -  Patients must have ECOG performance status (PS) of 0 - 2.

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to
             beginning treatment on this study. Nursing patients are excluded.

          -  Creatinine clearance &gt;50 ml/min

          -  Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT)
             or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) &lt; 3.0 x
             upper limit of normal (ULN)

          -  Serum total bilirubin &lt; 1.5 mg/dL. (except for unconjugated hyperbilirubinemia due to
             Gilbert's disease or secondary to MDS).

        Exclusion Criteria:

          -  Known positive status for human immunodeficiency virus (HIV) or hepatitis B or C

          -  Uncontrolled intercurrent illness including, but not limited to uncontrolled
             infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Patients receiving any other standard or investigational cytotoxic treatment for their
             hematologic malignancy

          -  Any medical condition which in the opinion of the investigator places the patient at
             an unacceptably high risk for toxicities

          -  Prior history of malignancy other than MDS (except basal cell or squamous cell
             carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been
             free of disease for ≥ 3 years

          -  Class III or IV cardiac disease, hypotension or severe hypertension, vasomotor
             instability, serious or uncontrolled cardiac dysrhythmias (including ventricular
             arrhythmias) at any time, acute myocardial infarction within the past 12 months,
             active uncontrolled angina pectoris or symptomatic arteriosclerotic blood vessel
             disease

          -  History of seizures, central nervous disorders, stroke within the last 12 months, or
             psychiatric disability thought to be clinically significant in the opinion of the
             investigator

          -  Prior history of autoimmune disease (including but not limited to systemic lupus,
             inflammatory bowel disease, and psoriasis)

          -  Patients with active peptic or esophageal ulcer disease or with past peptic ulcer or
             esophageal disease with a history of bleeding

          -  Patients continuing systemic treatment with clonidine, steroids, and/or H2 receptor
             blocking agents Patients with a history of hypersensitivity to histamine or histamine
             products, severe allergies to food or contrast media requiring treatment within the
             last five years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline BERTHON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myelodisplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno QUESNEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myelodisplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fenaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe francophone des Myelodisplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile de France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cochin</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>43033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hurriez</name>
      <address>
        <city>Lille</city>
        <zip>59057</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Heriot, dpt Hématologie Clinique</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Dpt, Hopital de l'Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean-Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Bequerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan Service d'Hématologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Céline Berthon, MD</name_title>
    <organization>Groupe Francophone des Myelodysplasies</organization>
  </responsible_party>
  <keyword>IPSS</keyword>
  <keyword>High risk</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Ceplene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

